Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma

The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here we show that treatment of NRAS-mutant melanoma cell lin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Rebecca, Vito W., Alicea, Gretchen M., Paraiso, Kim H.T., Lawrence, Harshani, Gibney, Geoffrey T., Smalley, Keiran S.M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4211982/
https://ncbi.nlm.nih.gov/pubmed/25130256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12303
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk